Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Supernus Pharm (NQ: SUPN )

36.60 +0.20 (+0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharm

< Previous 1 2 3 4 5 Next >
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Supernus Provides Regulatory Update for SPN-830
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Biotechnology And Healthcare, A Bit Of A Lull
Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors. 
Via Talk Markets
Recap: Supernus Pharmaceuticals Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Supernus Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. 
Via InvestorPlace
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to... 
Via Benzinga
Exposures Product Safety
Supernus Announces Third Quarter 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
Via Benzinga
Supernus to Participate in the Jefferies London Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
PDUFA Target Action Date of April 5, 2024 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Supernus to Participate in the Wells Fargo Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
Bethany L. Sensenig Joins Supernus’ Board of Directors
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Second Quarter 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.